Somatrogon-ghla
Orphan Drug Cold Chain RequiredFDA Approved
Contents
Description
Somatrogon-ghla is a recombinant human growth hormone indicated for pediatric patients. It is used for the treatment of growth hormone deficiency.
Indications & Therapeutic Use
Growth hormone deficiency
Linked Diseases:
Stimmler syndrome
C565968
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Buy / Source Somatrogon-ghla — GNH India
6 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Ngenla
24 mg/1.2mLinjection, solutionUSA
NGENLA 24mg
24 mg/1.2 mL (20 mg/mL)pfsIreland
NGENLA 60mg
60 mg/1.2 mL (50 mg/mL)pfsIreland
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Somatrogon-ghla
| Generic Name | Somatrogon-ghla |
| Brands | 1 brand available |
| Active Ingredient | Somatrogon-ghla |
| Drug Class | Growth hormone deficiency |
| Manufacturer | Pfizer |
| Dosage Forms | Injection |
| Medical Code | H01AC07 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02963098 |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes